Chemotherapy Manager now supports Inhalation as a route of administration across the end-to-end treatment workflow. The Inhalation route can be configured for applicable drugs and carried through regimen development, treatment planning, administration, billing, documentation, and reporting.
This enhancement introduces the Breast Cancer Risk Assessment (BCRAT) form within the 10G Assessments module. Users can now perform standardized breast cancer risk assessments directly within CureMD, calculate 5-year and lifetime risk, and retain the assessment inputs and calculated results as part of the patient's clinical documentation.
This enhancement improves patient safety by making active allergy information readily visible across key Chemotherapy Manager workflows. Active allergies are now displayed in Chemo Plan Reports, Drug Administration Reports, Administration Notes, and the Patient Banner, allowing clinicians to review important allergy information without navigating to other areas of the patient chart.
This enhancement introduces a configurable Weight Cap for eligible weight-based drugs, allowing practices to define a maximum weight used for dosage calculations. When a patient's recorded weight exceeds the configured threshold, the system automatically applies the capped weight during dose calculations and displays visual indicators throughout oncology workflows to identify capped dosing.
This enhancement introduces a redesigned Drug Forecasting Report that provides a more comprehensive view of upcoming medication requirements for oncology practices. The report includes enhanced forecasting, advanced filtering, patient-level details, improved NDC management, alternative drug selection, and expanded print and export capabilities to support inventory planning and reduce medication waste.
This enhancement significantly expands the Clinical Trials Research Module by providing a centralized workspace for managing research data, trial documentation, sign-off workflows, and consolidated reporting. The updated module introduces new research sections, streamlined trial summary creation, enhanced report management, and improved collaboration for clinical research teams.
This enhancement introduces the Therapies Nearing Completion report within the Chemotherapy Manager Dashboard. The report enables practices to proactively identify patients whose chemotherapy therapies are approaching completion, helping providers review and extend treatment plans without relying on manual chart reviews.
This enhancement captures and displays plan/product type information from eligibility responses directly on the Charge page. Plan Type (EB04) and Plan Description (EB05) are now stored at the charge level for the applicable Date of Service (DOS), providing greater visibility into insurance plan details and reducing the need for manual review of eligibility responses.
This enhancement adds direct access to drug flagging functionality within the Treatment Flowsheet. Users can now apply drug-level flags without leaving the treatment workflow, improving efficiency when managing medications in the Chemotherapy Manager.
This enhancement allows users to change a Resolved Adverse Event back to Active status when additional follow-up, updates, or ongoing monitoring is required. The feature restores editability while preserving key event information and maintaining accurate adverse event tracking.
Posted On: Oct 20, 2026
Posted On: Oct 20, 2026
Posted On: Oct 20, 2026
Posted On: Oct 20, 2026
Posted On: Oct 20, 2026
Posted On: Oct 20, 2026